Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis

NCT07471503 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis (MF)
HSCT

Interventions

DRUG: Gecacitinib (also known as Jaktinib)

Sponsor

Institute of Hematology & Blood Diseases Hospital, China